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Balloon aortic valvuloplasty in the era of 
transcatheter aortic valve implantation 
(TAVI): an opportunity to revisit a previously 
discouraged treatment option
metal stents. This was followed by balloon aortic valvuloplasty (BAV) 
with a 22 x 40mm TyshakTM balloon (Nu-MedTM Hopkinton, NY) under 
rapid ventricular pacing. The patient tolerated the procedure poorly 
with systolic blood pressures of 60mmHg. He recovered well though 
and at one month post procedure his functional class had improved to 
NYHA class 2. At repeat transthoracic echocardiography the mean 
gradient over the aortic valve had increased to 33mmHg with an 
increase in his LVEF to 35%. He was subsequently re-presented and 
accepted for conventional surgery in the form of prosthetic aortic valve 
replacement.
BACKGROUND
BAV was first performed in the 1980s with a number of groups 
describing fairly large series of experience with this procedure in a 
short period of time.(1-5) BAV enlarges the stenosed valve orifice by 
3 mechanisms: Stretching of valve tissue; rupturing of commis-
sural fusion; and release of calcific deposits. The last mechanism is 
probably the most effective in both tricuspid and bicuspid forms 
of AS to render the cusps more flexible and able to open and close 
effectively. Letac, et al. demonstrated on both fresh post-mortem 
specimens and also on post-mortem examination of cases that 
had had balloon valvuloplasty during life, that the marked increase 
in valve area obtained by the dilatation procedure was due to 
this mechanism.(3) Three dimensional volume-rendering computer 
tomography has further added to our understanding of the patho-
physiology that calcification stretching into the surrounding aortic 
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COMMENTARY
CLINICAL VIGNETTE
A 74-year old man was referred to our unit with a short history of 
progressive dyspnoea, NYHA grade 4 at the time of referral. He had a 
past medical history of bladder resection for malignancy and had a 
functioning cystostomy. Clinical examination revealed signs of aortic 
valve stenosis (AS) which was confirmed with echocardiography: His 
LVEF was only 15% with severe AS evidenced by a valve area of 
0.5cm2. The mean gradient over the valve was 20mmHg in keeping 
with low gradient-low flow AS.
Angiography revealed critical stenosis at the bifurcation of the left main 
stem. His log EuroSCORE predicted 30-day mortality was 40%. He 
was presented at our multi-disciplinary cardiothoracic surgery meeting 
for aortic valve replacement and coronary artery bypass grafting. Due 
to the high risk for the procedure he was turned down. As we do not 
have access to transcatheter aortic valve implantation (TAVI) at our 
academic institution I recommended medical treatment. The patient 
was adamant that this was unacceptable as he was still employed 
and depended on his income. After obtaining written informed consent 
we proceeded to perform left main bifurcation stenting with 2 bare 
Balloon aortic valvuloplasty (BAV) was described in the 
1980’s but early enthusiasm was kerbed by results indica-
ting risk of stroke and early restenosis. It therefore fell out 
of favour and is only indicated as a bridge to defi nitive treat-
ment in the majority of cases. With the advent of trans-
catheter aortic valve implantation (TAVI) as a new form of 
defi nitive treatment in high risk patients with aortic stenosis, 
there may be a new role for BAV.   SAHeart 2012; 9:96-99
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vascular wall limits the movements of the valve cusps and that it 
could, in all likelihood, also be improved by BAV.
COMPLICATIONS
Severe AR after the dilatation is fortunately rare (2% in the early 
series) but may be very poorly tolerated by the patient. Stroke can 
be a devastating complication but determining accurate rates is 
difficult as this complication tends to be underreported.(2,5,6) Letac 
found in their series of 213 patients that only 3 patients developed 
acute strokes during the procedure but late stroke was not 
reported. The best data is probably from the NHLBI registry where 
stroke was encountered in 3% of cases.(7) Other investigators did 
not comment on this complication. This initial enthusiasm was 
kerbed by a report of 84 patients by Block and Palacios, who found 
that although all cases had immediate improvement in symptoms, 
at a mean follow up of 5.5 months there was recurrence of 
symptoms, death or haemodynamic evidence of restenosis at 
repeat catheterisation in 56% of their patients.(6) An attempt at 
slowing down the restenosis rate was made by using external 
radiation as described in the Radiation Following Percutaneous 
Balloon Aortic Valvuloplasty to Prevent Restenosis (RADAR) pilot 
trial. Restenosis in the RADAR pilot study was 20% at 12 months 
in a population with an average age of 89 years suggesting utility 
in elderly patients.(8) This finding has however not been validated 
by others and is not widely used. The rapid rate of restenosis has 
led to a reduction in the number of BAV procedures performed 
and as a rule BAV should not be offered as standalone treatment. 
DOES THE DARK CLOUD HAVE A SILVER LINING?
With the advent of transcatheter aortic valve implantation (TAVI) 
as a definitive treatment option for high risk patients with degen-
erative AS should we reconsider our indications for BAV? During 
the TAVI procedure the patient is exposed to a BAV as predilata-
tion, but in contrast to isolated BAV this is offered as part of a 
definitive treatment plan. Another question raised is what the 
impact of newer techniques and equipment would have on pro-
cedural safety. Several technical and procedural improvements 
are now available for BAV that did not exist 20 years ago when 
Cribier first described the procedure.(9) Rapid ventricular pacing 
(180 to 220 beats per minute) is now utilised to arrest mecha-
nical systole to preserve balloon stability across the aortic valve 
during inflation. Furthermore, inflation–deflation times are faster 
(generally 3 seconds as opposed to an average of 23 seconds in 
the NHLBI registry of 674 cases).(7) The procedure is no longer 
performed via an antegrade transvenous route and modern bal-
loons can be passed through sheaths as small as 7-French. 
Cribier’s group published a further cohort 10 years after the initial 
procedure: Of 86 patients ≥80 years of age who received BAV 
via the retrograde approach, no myocardial perforations occur-
red and only 1 patient developed severe aortic regurgitation. Of 
these 86 patients only 1 suffered stroke and the overall peripro-
cedural mortality was 2.2%.(10) Whether this indicates a temporary 
satisfactory result in patients who are not candidates for valve 
replacement is debatable, however this procedure is offered to 
numerous patients in some centres with some even advocating 
repeated procedures as a reasonable option.(11)  
The landmark PARTNER trial of TAVI versus standard medical 
treatment was in fact criticised for the fact that the standard 
treatment arm included BAV in 84% of patients. This certainly 
does not reflect standard treatment in South Africa. It is note-
worthy that balloon aortic valvuloplasty changed from a class III to 
a class IIb recommendation in the most recent guidelines of the 
American College of Cardiology and American Heart Association 
(AHA)(12) and is also a class IIb recommendation in the European 
Society of Cardiology Guidelines(13) in the setting of severe AS.
ESTABLISHED INDICATIONS FOR BAV
There are a small number of clinical scenarios in which it remains 
appropriate to perform BAV.(14) These include young people with 
sub-aortic ridges or mobile valve leaflets and patients with critical 
AS who require other urgent high risk surgical procedures where 
aortic valve replacement is not an option. In the latter group a 
multi-disciplinary team approach to evaluate the different treatment 
options is absolutely mandatory.(15) These indications are however, 
not the focus of this discussion.
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Potential new indications for BAV in the TAVI era include:
 ■ Patients who do not qualify for TAVI on grounds of poor 
LV function or haemodynamic instability. Both the Edwards 
SAPIENTM and MedtronicTM CoreValveTM devices are registe-
red to be used in patients with an ejection fraction of greater 
than 20%. In unstable cases who are otherwise potentially 
suitable candidates for TAVI our group has performed BAV 
with good results. The patient is afforded the time to stabilise, 
with usually an increase in systolic function, and the option of 
either TAVI or even open valve replacement can be performed 
under much more controlled circumstances.
 ■ To evaluate the contribution AS makes to a patient with 
multiple comorbidities that may be responsible for symp-
toms. TAVI candidates very often have a multitude of comor-
bidities that may cause dyspnoea and there is often doubt as 
to whether the AS is a significant contributor. Echocardio-
graphy performed by a skilled operator can usually provide a 
reasonable answer to this question, but in selected cases 
uncertainty may remain. In these rare cases BAV may be per-
formed as a “diagnostic” procedure to determine the contri-
bution the AS makes to symptoms of breathlessness. Justifying 
the risk of BAV in this setting has to be done in conjunction 
with an informed patient. It has been our experience that in 
patients with multiple comorbidities where BAV was used as 
a tool to stabilise them, non-response to BAV was almost 
invariably associated with a poor response to TAVI. Although 
this has not been described by others our team has incor-
porated a poor response to BAV as a relative contra-indication 
to TAVI. 
 ■ Buying time for a patient who is unwell and awaiting TAVI. 
The TAVI procedure is often delayed for a number of logist-
ical reasons, including: Waiting for a proctor to be available 
to help with the case; waiting for the correct size device to 
become available; and waiting for funders to decide if a pro-
cedure will be funded. In such cases it is reasonable to offer 
the patient BAV if the clinical condition is such that a pro-
longed delay is deemed a significant risk.
 ■ To evaluate if a patient with AS of uncertain severity will 
respond to TAVI. Elderly patients with calcified aortic valves 
often present a diagnostic dilemma with regards to AS 
severity. Paradoxical low gradient with good ejection fraction 
is one such scenario. Despite all the diagnostic tests avail-
able, including valvulo-arterial impedance, transoesophageal 
echocardiography and dobutamine stress echo there some-
times is uncertainty as to whether the AS is truly severe. We 
have used BAV in such cases and if the patient has a clear 
symptomatic response to BAV we would offer TAVI.
CONCLUSION 
BAV is a procedure that fell out of favour 10 years after first being 
used because of rapid restenosis rates and the perception that it 
carries a high risk. Due to improvements in technique and the 
new modality of TAVI it may however be considered as a bridge 
to definitive treatment in specific clinical scenarios.
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